市場調查報告書

急性疼痛 - 市場洞察,流行病學,預測

Acute Pain- Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 905943
出版日期 內容資訊 英文 324 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
急性疼痛 - 市場洞察,流行病學,預測 Acute Pain- Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年08月01日內容資訊: 英文 324 Pages
簡介

本報告提供主要7個國家(英國,德國,法國,義大利,西班牙,日本)的急性疼痛市場調查,市場概要,疾病概要和現行的治療方法,新藥的簡介,以總及各國的市場趨勢,流行病學的預測,市場規模,患者數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 急性疼痛市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 急性疼痛:疾病背景和概要

  • 簡介
  • 急性疼痛的種類
  • 急性疼痛的原因
  • 急性疼痛的症狀
  • 急性疼痛的病理生理學
  • 急性疼痛的診斷

第4章 流行病學和患者人口

  • 主要7個國家的急性疼痛的總患者數
  • 主要7個國家的急性疼痛的患者數:病情

第5章 美國的流行病學

  • 假設和根據
  • 急性疼痛的總患者數
  • 急性疼痛的患者數:各重症度

第6章 歐洲5個國家的流行病學

  • 假設和根據
  • 德國
    • 急性疼痛的總患者數
    • 急性疼痛的患者數:各重症度
  • 法國
  • 義大利
  • 西班牙
  • 英國

第7章 日本的流行病學

  • 假設和根據
  • 急性疼痛的總患者數
  • 急性疼痛的患者數:各重症度

第8章 治療流程與現行治療

  • 急性止痛與管理
    • 藥理學性
    • 非藥理學性
  • 急性手術後疼痛的治療流程
  • 急性疼痛的提倡指南

第9章 未滿足需求

第10章 已上市產品

  • LICART(Diclofenac Epolamine):IBSA Institut Biochimique SA/帝國製藥
    • 產品說明
    • 法規的里程碑
    • 臨床開發活動
    • 安全性和有效性
    • 產品簡介
  • DSUVIA (Sufentanil):AcelRx Pharmaceuticals
  • APADAZ:KemPharm
  • Zalviso:AcelRx Pharmaceuticals
  • Tivorbex (Indomenthacin):Iroko Pharmaceuticals
  • Clinical Trial Information
  • Zorvolex (Diclofenac):EGALET
  • OXECTA:King Pharmaceuticals Inc.
  • EXPAREL:Pacira Pharmaceuticals
  • ZIPSOR:Depomed
  • Nucynta:Ortho-McNeil-Janssen
  • OFIRMEV:Mallinckrodt
  • ULTRACET:Janssen Pharms

第11章 新藥

  • 關鍵交叉競爭
  • Ubrogepant:Allergan
    • 產品說明
    • 開發趨勢
    • 臨床開發活動
    • 臨床試驗資訊
    • 安全性和有效性
    • 產品簡介
  • Oliceridine injection (TRV130):Trevena
    • 開發趨勢
    • 臨床開發
    • 臨床試驗資訊
  • HTX-011:Heron Therapeutics
  • CL-108:Charleston Laboratories
  • Dexketoprofen Tramadol:Menarini Group
  • MR308:Mundipharma Research GmbH & Co KG/Laboratorios del Dr. Esteve, S.A.
  • CR845:Cara Therapeutics
  • Capsaicin/Diclofenac:Boehringer Ingelheim
  • Ibuprofen:Boehringer Ingelheim
  • Methoxyflurane:Medical Developments International Limited
  • CA-008:Concentric Analgesics
  • VX-150:Vertex Pharmaceuticals Incorporated
  • CL-H1T:Charleston Laboratories
  • Tolperisone:Neurana Pharmaceuticals
  • NTM-001:Neumentum Pharmaceuticals

第12章 主要7個國家的急性疼痛市場

  • 市場規模(以金額為準)
  • 市場規模(以數量為準)

第13章 美國:市場預測

  • 美國
    • 總市場規模(以金額為準)
    • 總市場規模(以數量為準)
    • 市場規模:各治療藥物

第14章 歐洲5個國家:市場預測

  • 德國
    • 總市場規模(以金額為準)
    • 總市場規模(以數量為準)
    • 市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第15章 日本:市場預測

  • 日本
    • 總市場規模(以金額為準)
    • 總市場規模(以數量為準)
    • 市場規模:各治療藥物

第16章 市場成長要素

第17章 市場障礙

第18章 附錄

  • 調查手法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章:關於DelveInsight

目錄
Product Code: DIMI0668

DelveInsight's 'Acute Pain- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Acute Pain in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Acute Pain from 2017 to 2028 segmented by the seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Acute Pain- Disease Understanding and Treatment Algorithm

Acute pain is defined as "an expected physiologic experience to injurious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries." The presence of pain often means that something is wrong. Each individual is the best judge of his or her own pain. There are different types of pain, basically, they are categorized into two forms, i.e., acute pain and chronic pain.

Acute pain is a type of pain that typically lasts less than 3-6 months. It is of short duration but it gradually resolves as the injured tissues heal. Acute pain is distinct from chronic pain and is relatively more sharp and severe. Acute pain may be primarily caused by surgery, trauma, or other medical illness. The data on incidence and prevalence of pain, and specifically acute pain shows variety.

For the assessment acute pain, various type of scaling tools are used. These scales are of two types; one dimensional and multidimensional scaling tool. The former (i.e., rating scales) usually assess a single dimension of pain, patient self-report of pain intensity. Visual Analogue Scale (VAS), Numerical Rating Scale (NRS), Faces pain scale (FPS), McGill Pain Questionnaire (MPQ) are commonly used tool to check the severity of acute pain.

The DelveInsight's Acute Pain market report gives a thorough understanding of the acute Pain by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Pain in the US, Europe, and Japan.

Acute Pain - Epidemiology

The acute pain epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight's report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Patient Pool with Acute Pain by Medical Condition and Severity Specific Patient Pool of Acute Pain] scenario of acute pain in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028.

DelveInsight's epidemiology model for Acute Pain has assessed the total patient pool with Acute Pain, based on the proportion of population undergoing surgery, trauma injury and other medical illness, respectively. We have assessed that the patient pool of Acute Pool in the 7MM countries was nearly 119,619,121 cases in 2017. DelveInsight's estimate suggests the United States showed the highest number of cases with Acute Pain, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 74.32% of total cases, for Acute Pain, in the 7MM countries in 2017.

As per DelevInsight's analyst, of the population undergoing surgery in the US, nearly 80% experience acute postoperative pain, thereby contributing 41,766,061 patients to the Acute Pain population in 2017. Furthermore, among the patients with trauma injury in the US, 34,068,366 patients were contributed to the Acute Pain patient population. In contrast, the patient contribution by other acute medical illness was observed to be lowest in 2017.

Among the EU-5 countries, Germany accounted for the highest number of cases for acute pain, followed by the patient pool observed in the United Kingdom. In contrast, Spain accommodated the lowest number of cases for acute pain in this region.

Based on the severity of the disease, we have observed that patients with moderate pain accounted for the largest patient pool, followed by the number of patients with mild pain, while those with severe pain accommodated for the least patient pool. However, an overall trend was observed such that moderate-severe pain together accounted for highest patient pool in the 7MM countries.

Acute Pain- Drug Chapters

This segment of the acute pain report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

For the treatment of acute pain there are many drugs are available of NSAIDs and Opioids class. LICART (Diclofenac Epolamine; IBSA Institut Biochimique SA/ Teikoku Seiyaku), DSUVIA (Sufentanil; AcelRx Pharmaceuticals), APADAZ (KemPharm), Zalviso (AcelRx Pharmaceuticals), Tivorbex (Indomenthacin; Iroko Pharmaceuticals), Zorvolex (Diclofena; EGALET), OXECTA (King Pharmaceuticals Inc), EXPAREL (Pacira Pharmaceuticals), ZIPSOR (Depomed), Nucynta (Ortho-McNeil-Janssen,) and OFIRMEV (Mallinckrodt) are approved drugs for the acute pain treatment and management

LICART is recently approved. LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. It is diclofenac epolamine that has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac is not clear yet and is thought to inhibit cyclooxygenase (COX-1 and COX-2). Diclofenac is also a potent inhibitor of prostaglandin synthesis in vitro.

On the other hand, DSUVIA is an opioid agonist contains sufentanil and is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is administered in the form of the tablet sublingually to the patient. However, the intensity of pain must be severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

APADAZ is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen developed by KemPharm's and is indicated for the short-term (no more than 14 days).

ZAlVISO is indicated for the management of acute moderate to severe post-operative pain in adult patients. Zalviso sublingual tablets are to be self-administered by the patient in response to pain using the Zalviso administration device. Zalviso was developed in order to produce an orally available formulation of the opioid analgesic and sedative sufentanil, used in intravenous anesthetic regimens in operating theatres. TIVORBEX is an non-steroidal anti-inflammatory drugs (NSAIDs) indicated for the treatment of mild-to-moderate acute pain in adults.

Acute Pain- Market Outlook

The acute pain market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The therapeutic market of acute pain in the seven major markets is expected USD 1,962.02 million in 2017 for the study period (2017-2028). The United States accounted for the highest market size by value, among the 7MM countries, with USD 1,568.82 million share in its box in 2017. Among the EU-5 countries, we have assessed that Germany contributed the maximum share, with USD 110.16 million in 2017, followed by France. On the other hand Spain attained last position in the race of contribution for market size by value. Japan contributed a share of USD 109.97 million market size by value, to the total 7MM market size, in 2017.

DelveInsight's assessments suggests that the 7MM market size of acute pain by volume was observed to be 1,004,842,486 in the year 2017, which is anticipated to decline during the forecast period [2019-2028]. This is attributed to the fact that the dosage strength and treatment cycle of the emerging therapies is significantly lower, in comparison to the currently prescribed therapies. Similar to the case of market size by value, we have observed that the market size of acute pain by volume was highest in the United States among the 7MM countries, and in Germany in the EU-5 region.

Advancement in development of novel drug candidate by various pharmaceutical companies the dynamics of acute pain market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028. There are presently many drugs focused on the treatment of acute pain, which are expected to enter the market during the forecast period [2019-2028].

Acute Pain - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Acute Pain market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and advancement in the research and development of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for acute Pain.

More than a dozen companies have shifted their focus towards this therapeutic area. To name a few: AcelRx Pharmaceuticals, Neurana Pharmaceuticals, IBSA/Teikoku Seiyaku, Concentric Analgesics, Charleston Laboratories, Medical Developments International Limited, Vertex Pharmaceuticals Incorporated, Mundipharma Research GmbH & Co KG, Trevena, Menarini Group, Cara Therapeutics, Boehringer Ingelheim, Laboratorios del Dr. Esteve, S.A., Allergan, Antibe Therapeutics, Heron Therapeutics, and others. While some of these are in the early stage of development, yet others have recently been approved, however, they have not yet been launched in the US treatment market.

Acute Pain Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Pain Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Acute Pain Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Acute Pain market
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Pain market
  • To understand the future market competition in the Acute Pain market.

Table of Contents

1. Key Insights

2. Acute Pain Market Overview at a Glance

  • 2.1. Market (%) Distribution of Acute Pain in 2017
  • 2.2. Market (%) Distribution of Acute Pain in 2028

3. Acute Pain: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Common Types of Acute Pain
  • 3.3. Causes of Acute Pain
  • 3.4. Signs and Symptoms of Acute Pain
  • 3.5. Pathophysiology of Acute Pain
    • 3.5.1. The Physiology of the Acute Pain Pathway
    • 3.5.2. Effects on Key Target Organs
  • 3.6. Diagnosis of Acute Pain
    • 3.6.1. Common Assessment Tools
    • 3.6.2. Various Grading Scales used for Diagnosis of Acute Pain
    • 3.6.3. Psychometric Testing
    • 3.6.4. Pain Assessment
    • 3.6.5. Goals and Elements of the Initial Assessment
    • 3.6.6. Pre and Post-Operative Assessment and patient Education Recommendation

4. Epidemiology and Patient Population

  • 4.1. Total Patient Pool with Acute Pain in the 7MM
  • 4.2. Number of Patients with Acute Pain by Medical Condition in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Patient Pool with Acute Pain in the United States
  • 5.3. Severity Specific Patient Pool of Acute Pain in the United States

6. EU5 Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Germany Epidemiology
    • 6.2.1. Total Patient Pool with Acute Pain in Germany
    • 6.2.2. Severity Specific Patient Pool of Acute Pain in Germany
  • 6.3. France Epidemiology
    • 6.3.1. Total Patient Pool with Acute Pain in France
    • 6.3.2. Severity Specific Patient Pool of Acute Pain in France
  • 6.4. Italy Epidemiology
    • 6.4.1. Total Patient Pool with Acute Pain in Italy
    • 6.4.2. Severity Specific Patient Pool of Acute Pain in Italy
  • 6.5. Spain Epidemiology
    • 6.5.1. Total Patient Pool with Acute Pain in Spain
    • 6.5.2. Severity Specific Patient Pool of Acute Pain in Spain
  • 6.6. United Kingdom Epidemiology
    • 6.6.1. Total Patient Pool with Acute Pain in the United Kingdom
    • 6.6.2. Severity Specific Patient Pool of Acute Pain in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Patient Pool with Acute Pain in Japan
  • 7.3. Severity Specific Patient Pool of Acute Pain in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Treatment and Management of Acute Pain
    • 8.1.1. Pharmacological Methods to Treat Acute Pain
    • 8.1.2. Non-Pharmacological Methods to Treat Acute Pain
  • 8.2. Treatment Algorithm for Acute Post-Operative Pain
  • 8.3. Proposed Guidelines for Acute Pain
    • 8.3.1. American Academy of Family Physicians: Pharmacologic Therapy for Acute Pain
    • 8.3.2. American Society of Anesthesiologists Task Force (ASATK) on Acute Pain Management: Practice Guidelines for Acute Pain Management in the Perioperative Setting
    • 8.3.3. The American Academy of Pediatrics (AAP) and the American Pain Society (APS)
    • 8.3.4. German Interdisciplinary Society of Pain Management (DIVS) Guidelines

9. Unmet Needs

10. Marketed Products

  • 10.1. LICART (Diclofenac Epolamine): IBSA Institut Biochimique SA/ Teikoku Seiyaku
    • 10.1.1. Product Description
    • 10.1.2. Regulatory Milestones
    • 10.1.3. Clinical Developmental Activities
    • 10.1.4. Safety and Efficacy
    • 10.1.5. Product Profile
  • 10.2. DSUVIA (Sufentanil): AcelRx Pharmaceuticals
    • 10.2.1. Product Description
    • 10.2.2. Regulatory Milestones
    • 10.2.3. Clinical Development
    • 10.2.4. Clinical Trials Information
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
  • 10.3. APADAZ: KemPharm
    • 10.3.1. Product Description
    • 10.3.2. Regulatory Milestones
    • 10.3.3. Clinical Development
    • 10.3.4. Product Profile
  • 10.4. Zalviso: AcelRx Pharmaceuticals
    • 10.4.1. Product Description
    • 10.4.2. Regulatory Milestones
    • 10.4.3. Clinical Development
    • 10.4.4. Clinical Trials Information
    • 10.4.5. Safety and Efficacy
    • 10.4.6. Product Profile
  • 10.5. Tivorbex (Indomenthacin): Iroko Pharmaceuticals
    • 10.5.1. Product Description
    • 10.5.2. Regulatory Milestones
    • 10.5.3. Clinical Developmental Activities
    • 10.5.4. Clinical Trial Information
    • 10.5.5. Safety and Efficacy
    • 10.5.6. Product Profile
  • 10.6. Zorvolex (Diclofenac): EGALET
    • 10.6.1. Product Description
    • 10.6.2. Regulatory Milestones
    • 10.6.3. Clinical Developmental Activities
    • 10.6.4. Clinical Trial Information
    • 10.6.5. Safety and Efficacy
    • 10.6.6. Product Profile
  • 10.7. OXECTA: King Pharmaceuticals Inc.
    • 10.7.1. Product Description
    • 10.7.2. Regulatory Milestones
    • 10.7.3. Clinical Developmental Activities
    • 10.7.4. Safety and Efficacy
    • 10.7.5. Product Profile
  • 10.8. EXPAREL: Pacira Pharmaceuticals
    • 10.8.1. Product Description
    • 10.8.2. Regulatory Milestones
    • 10.8.3. Clinical Development
    • 10.8.4. Clinical Trials Information
    • 10.8.5. Safety and Efficacy
    • 10.8.6. Product Profile
  • 10.9. ZIPSOR: Depomed
    • 10.9.1. Product Description
    • 10.9.2. Regulatory Milestones
    • 10.9.3. Clinical Developmental Activities
    • 10.9.4. Clinical Trial Information
    • 10.9.5. Safety and Efficacy
    • 10.9.6. Product Profile
  • 10.10. Nucynta: Ortho-McNeil-Janssen
    • 10.10.1. Product Description
    • 10.10.2. Regulatory Milestones
    • 10.10.3. Clinical Developmental Activities
    • 10.10.4. Clinical Trial Information
    • 10.10.5. Safety and Efficacy
    • 10.10.6. Product Profile
  • 10.11. OFIRMEV: Mallinckrodt
    • 10.11.1. Product Description
    • 10.11.2. Regulatory Milestones
    • 10.11.3. Clinical Developmental Activities
    • 10.11.4. Clinical Trial Information
    • 10.11.5. Safety and Efficacy
    • 10.11.6. Product Profile
  • 10.12. ULTRACET: Janssen Pharms
    • 10.12.1. Product Description
    • 10.12.2. Regulatory Milestones
    • 10.12.3. Clinical Developmental Activities
    • 10.12.4. Clinical Trial Information
    • 10.12.5. Safety and Efficacy
    • 10.12.6. Product Profile

11. Emerging Therapies

  • 11.1. Key Cross Competition
  • 11.2. Ubrogepant: Allergan
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Developmental Activities
    • 11.2.4. Clinical Trial Information
    • 11.2.5. Safety and Efficacy
    • 11.2.6. Product Profile
  • 11.3. Oliceridine injection (TRV130): Trevena
    • 11.3.1. Product Description
    • 11.3.2. Other Development Activities
    • 11.3.3. Clinical Development
    • 11.3.4. Clinical Trials Information
    • 11.3.5. Safety and Efficacy
    • 11.3.6. Product Profile
  • 11.4. HTX-011: Heron Therapeutics
    • 11.4.1. Product Description
    • 11.4.2. Other Developmental Activities
    • 11.4.3. Clinical Development
    • 11.4.4. Clinical Trials Information
    • 11.4.5. Safety and Efficacy
    • 11.4.6. Product Profile
  • 11.5. CL-108: Charleston Laboratories
    • 11.5.1. Product Description
    • 11.5.2. Other Developmental Activities
    • 11.5.3. Clinical Development
    • 11.5.4. Clinical Trials Information
    • 11.5.5. Safety and Efficacy
    • 11.5.6. Product Profile
  • 11.6. Dexketoprofen Tramadol: Menarini Group
    • 11.6.1. Product Description
    • 11.6.2. Other Development Activities
    • 11.6.3. Clinical Development
    • 11.6.4. Clinical Trials Information
    • 11.6.5. Safety and Efficacy
    • 11.6.6. Product Profile
  • 11.7. MR308: Mundipharma Research GmbH & Co KG/Laboratorios del Dr. Esteve, S.A.
    • 11.7.1. Product Description
    • 11.7.2. Other Development Activities
    • 11.7.3. Clinical Development
    • 11.7.4. Clinical Trials Information
    • 11.7.5. Product Profile
  • 11.8. CR845: Cara Therapeutics
    • 11.8.1. Product Description
    • 11.8.2. Other Developmental Activities
    • 11.8.3. Clinical Development
    • 11.8.4. Clinical Trials Information
    • 11.8.5. Safety and Efficacy
    • 11.8.6. Product Profile
  • 11.9. Capsaicin/Diclofenac: Boehringer Ingelheim
    • 11.9.1. Product Description
    • 11.9.2. Clinical Development
    • 11.9.3. Clinical Trials Information
    • 11.9.4. Product Profile
  • 11.10. Ibuprofen: Boehringer Ingelheim
    • 11.10.1. Product Description
    • 11.10.2. Other Developmental Activities
    • 11.10.3. Clinical Development
    • 11.10.4. Clinical Trials Information
    • 11.10.5. Safety and Efficacy
    • 11.10.6. Product Profile
  • 11.11. Methoxyflurane: Medical Developments International Limited
    • 11.11.1. Product Description
    • 11.11.2. Other Development Activities
    • 11.11.3. Clinical Development
    • 11.11.4. Clinical Trials Information
    • 11.11.5. Safety and Efficacy
    • 11.11.6. Product Profile
  • 11.12. CA-008: Concentric Analgesics
    • 11.12.1. Product Description
    • 11.12.2. Other Development Activities
    • 11.12.3. Clinical Development
    • 11.12.4. Clinical Trials Information
    • 11.12.5. Safety and Efficacy
    • 11.12.6. Product Profile
  • 11.13. VX-150: Vertex Pharmaceuticals Incorporated
    • 11.13.1. Product Description
    • 11.13.2. Other Development Activities
    • 11.13.3. Clinical Development
    • 11.13.4. Clinical Trials Information
    • 11.13.5. Safety and Efficacy
    • 11.13.6. Product Profile
  • 11.14. CL-H1T: Charleston Laboratories
    • 11.14.1. Product Description
    • 11.14.2. Other Developmental Activities
    • 11.14.3. Clinical Development
    • 11.14.4. Clinical Trials Information
    • 11.14.5. Product Profile
  • 11.15. Tolperisone: Neurana Pharmaceuticals
    • 11.15.1. Product Description
    • 11.15.2. Other Development Activities
    • 11.15.3. Clinical Development
    • 11.15.4. Clinical Trials Information
    • 11.15.5. Safety and Efficacy
    • 11.15.6. Product Profile
  • 11.16. NTM-001: Neumentum Pharmaceuticals
    • 11.16.1. Product Description
    • 11.16.2. Other Developmental Activities
    • 11.16.3. Clinical Developmental Activities
    • 11.16.4. Safety and Efficacy
    • 11.16.5. Product Profile

12. Acute Pain: 7MM Market Analysis

  • 12.1. Market Size of Acute Pain by Value in 7MM
  • 12.2. Market Size of Acute Pain by Volume in 7MM

13. United States: Market Outlook

  • 13.1. United States Market Size
    • 13.1.1. Total Market size of Acute Pain by Value in the United States
    • 13.1.2. Market Size of Acute Pain by Therapies in the United States
    • 13.1.3. Total Market size of Acute Pain by Volume in the United States

14. EU-5 countries: Market Outlook

  • 14.1. Germany Market Size
    • 14.1.1. Total Market size of Acute Pain by Value in Germany
    • 14.1.2. Market Size of Acute Pain by therapies in Germany
    • 14.1.3. Total Market size of Acute Pain by Volume in Germany
  • 14.2. France Market Size
    • 14.2.1. Total Market size of Acute Pain by Value in France
    • 14.2.2. Market Size of Acute Pain by therapies in France
    • 14.2.3. Total Market size of Acute Pain by Volume in France
  • 14.3. Italy Market Size
    • 14.3.1. Total Market size of Acute Pain by Value in Italy
    • 14.3.2. Market Size of Acute Pain by therapies in Italy
    • 14.3.3. Total Market size of Acute Pain by Volume in Italy
  • 14.4. Spain Market Size
    • 14.4.1. Total Market size of Acute Pain by Value in Spain
    • 14.4.2. Market Size of Acute Pain by therapies in Spain
    • 14.4.3. Total Market size of Acute Pain by Volume in Spain
  • 14.5. United Kingdom Market Size
    • 14.5.1. Total Market size of Acute Pain by Value in the United Kingdom
    • 14.5.2. Market Size of Acute Pain by therapies in the UK
    • 14.5.3. Total Market size of Acute Pain by Volume in the United Kingdom

15. Japan Market Outlook

  • 15.1. Japan Market Size
    • 15.1.1. Total Market size of Acute Pain by Value in Japan
    • 15.1.2. Market Size of Acute Pain by therapies in Japan
    • 15.1.3. Total Market size of Acute Pain by Volume in Japan

16. Market Drivers

17. Market Barriers

18. Appendix

  • 18.1. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Tables

  • TABLE 1: COMMON TYPES OF ACUTE PAIN
  • TABLE 2: UNIDIMENSIONAL PAIN ASSESSMENT TOOLS
  • TABLE 3: MULTIDIMENSIONAL PAIN ASSESSMENT TOOLS
  • TABLE 4: INFORMATION FROM THE PATIENT HISTORY
  • TABLE 5: CHARACTERISTICS OF PAIN TYPES
  • TABLE 6: ASSESSMENT CHALLENGES AND APPROACHES IN SPECIAL POPULATIONS
  • TABLE 7: POSTOPERATIVE ASSESSMENT AND PATIENT EDUCATION RECOMMENDATIONS
  • TABLE 8: PHYSICAL EXAMINATION OF A PATIENT WITH PAIN
  • TABLE 9: DIAGNOSTIC TESTS EXAMPLES FOR ACUTE PAIN
  • TABLE 10: PREOPERATIVEASSESSMENT AND PATIENT EDUCATION RECOMMENDATIONS
  • TABLE 11: POST-OPERATIVE ASSESSMENT AND PATIENT EDUCATION RECOMMENDATIONS
  • TABLE 12: TOTAL PATIENT POOL WITH ACUTE PAIN IN THE 7MM (2017-2028)
  • TABLE 13: NUMBER OF PATIENTS WITH ACUTE PAIN BY MEDICAL CONDITION IN THE 7MM (2017-2028)
  • TABLE 14: TOTAL PATIENT POOL WITH ACUTE PAIN IN THE US (2017-2028)
  • TABLE 15: SEVERITY SPECIFIC PATIENT POOL OF ACUTE PAIN IN THE US (2017-2028)
  • TABLE 16: TOTAL PATIENT POOL WITH ACUTE PAIN IN GERMANY (2017-2028)
  • TABLE 17: SEVERITY SPECIFIC PATIENT POOL OF ACUTE PAIN IN GERMANY (2017-2028)
  • TABLE 18: TOTAL PATIENT POOL WITH ACUTE PAIN IN FRANCE (2017-2028)
  • TABLE 19: SEVERITY SPECIFIC PATIENT POOL OF ACUTE PAIN IN FRANCE (2017-2028)
  • TABLE 20: TOTAL PATIENT POOL WITH ACUTE PAIN IN ITALY (2017-2028)
  • TABLE 21: SEVERITY SPECIFIC PATIENT POOL OF ACUTE PAIN IN ITALY (2017-2028)
  • TABLE 22: TOTAL PATIENT POOL WITH ACUTE PAIN IN SPAIN (2017-2028)
  • TABLE 23: SEVERITY SPECIFIC PATIENT POOL OF ACUTE PAIN IN SPAIN (2017-2028)
  • TABLE 24: TOTAL PATIENT POOL WITH ACUTE PAIN IN THE UNITED KINGDOM (2017-2028)
  • TABLE 25: SEVERITY SPECIFIC PATIENT POOL OF ACUTE PAIN IN THE UNITED KINGDOM (2017-2028)
  • TABLE 26: TOTAL PATIENT POOL WITH ACUTE PAIN IN JAPAN (2017-2028)
  • TABLE 27: SEVERITY SPECIFIC PATIENT POOL OF ACUTE PAIN IN JAPAN (2017-2028)
  • TABLE 28: KEY RECOMMENDATIONS FOR PRACTICE
  • TABLE 29: STEPS FOR MEDICATIONS TO TREAT ACUTE PAIN IN ADULTS
  • TABLE 30: DSUVIA (SUFENTANIL), CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 31: ZALVISO, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 32: TIVORBEX (INDOMENTHACIN), CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 33: ZORVOLEX (DICLOFENAC), CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 34: EXPAREL, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 35: ZIPSOR, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 36: NUCYNTA (TAPENTADOL; CG5503), CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 37: OFIRMEV, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 38: ULTRACET, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 39: KEY CROSS COMPETITION OF EMERGING DRUGS
  • TABLE 40: KEY CROSS COMPETITION OF EMERGING DRUGS (CONTD.)
  • TABLE 41: KEY CROSS COMPETITION OF EMERGING DRUGS (CONTD.)
  • TABLE 42: UBROGEPANT, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 43: OLICERIDINE INJECTION (TRV130), CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 44: HTX-011, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 45: CL-108, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 46: DEXKETOPROFEN TRAMADOL, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 47: MR308, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 48: CR845, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 49: CAPSAICIN + DICLOFENAC, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 50: IBUPROFEN, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 51: METHOXYFLURANE, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 52: CA-008, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 53: VX-150, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 54: CL-H1T, CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 55: TOLPERISONE CLINICAL TRIAL DESCRIPTION, 2019
  • TABLE 56: MARKET SIZE OF ACUTE PAIN BY VALUE IN 7MM IN USD MILLION (2017-2028)
  • TABLE 57: MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) IN 7MM (2017-2028)
  • TABLE 58: LIST OF MARKETED DRUGS APPROVED BY THE US FDA FOR ACUTE PAIN
  • TABLE 59: EXPECTED LAUNCH DATE OF EMERGING DRUGS IN THE UNITED STATES
  • TABLE 60: THE US MARKET SIZE OF ACUTE PAIN BY VALUE IN USD MILLION (2017-2028)
  • TABLE 61:MARKET SIZE OF ACUTE PAIN BY THERAPIES IN THE UNITED STATES, IN USD MILLION (2017-2028)
  • TABLE 62: THE US MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) (2017-2028)
  • TABLE 63: EXPECTED LAUNCH DATE OF EMERGING DRUGS IN EU-5 COUNTRIES
  • TABLE 64: GERMANY MARKET SIZE OF ACUTE PAIN IN USD MILLION (2017-2028)
  • TABLE 65: MARKET SIZE OF ACUTE PAIN BY THERAPIES IN GERMANY, IN USD MILLION (2017-2028)
  • TABLE 66: GERMANY MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) (2017-2028)
  • TABLE 67: FRANCE MARKET SIZE OF ACUTE PAIN BY VALUE IN USD MILLION (2017-2028)
  • TABLE 68: MARKET SIZE OF ACUTE PAIN BY THERAPIES IN FRANCE, IN USD MILLION (2017-2028)
  • TABLE 69: FRANCE MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) (2017-2028)
  • TABLE 70: ITALY MARKET SIZE OF ACUTE PAIN BY VALUE IN USD MILLION (2017-2028)
  • TABLE 71: MARKET SIZE OF ACUTE PAIN BY THERAPIES IN ITALY, IN USD MILLION (2017-2028)
  • TABLE 72: ITALY MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) (2017-2028)
  • TABLE 73: SPAIN MARKET SIZE OF ACUTE PAIN BY VALUE IN USD MILLION (2017-2028)
  • TABLE 74: MARKET SIZE OF ACUTE PAIN BY THERAPIES IN SPAIN, IN USD MILLION (2017-2028)
  • TABLE 75: SPAIN MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) (2017-2028)
  • TABLE 76: THE UK MARKET SIZE OF ACUTE PAIN BY VALUE IN USD MILLION (2017-2028)
  • TABLE 77: MARKET SIZE OF ACUTE PAIN BY THERAPIES IN THE UNITED KINGDOM, IN USD MILLION (2017-2028)
  • TABLE 78: THE UK MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) (2017-2028)
  • TABLE 79: EXPECTED LAUNCH DATE OF EMERGING DRUGS IN JAPAN
  • TABLE 80: JAPAN MARKET SIZE OF ACUTE PAIN BY VALUE IN USD MILLION (2017-2028)
  • TABLE 81: MARKET SIZE OF ACUTE PAIN BY THERAPIES IN JAPAN, IN USD MILLION (2017-2028)
  • TABLE 82: JAPAN MARKET SIZE OF ACUTE PAIN BY VOLUME (IN '000) (2017-2028)

List of Figures

  • Figure 1: Types of Pain
  • Figure 1: Wong-Baker Faces Pain Rating Scale
  • Figure 2: Progression from Acute to Chronic Pain
  • Figure 3: Signs and Symptoms of Acute Pain
  • Figure 4: Afferent Nociceptive Pathway
  • Figure 5: Efferent Nociceptive pathway
  • Figure 6: Total Patient Pool with Acute Pain in the 7MM (2017-2028)
  • Figure 7: Number of Patients with Acute Pain by Medical Condition in the 7MM (2017-2028)
  • Figure 8: Total Patient Pool with Acute Pain in the US (2017-2028)
  • Figure 9: Patient Pool with Acute Pain by Medical Condition in the US (2017-2028)
  • Figure 10: Severity Specific Patient Pool of Acute Pain in the US (2017-2028)
  • Figure 11: Total Patient Pool with Acute Pain in Germany (2017-2028)
  • Figure 12: Patient Pool with Acute Pain by Medical Condition in Germany (2017-2028)
  • Figure 13: Severity Specific Patient Pool of Acute Pain in Germany (2017-2028)
  • Figure 14: Total Patient Pool with Acute Pain in France (2017-2028)
  • Figure 15: Patient Pool with Acute Pain by Medical Condition in France (2017-2028)
  • Figure 16: Severity Specific Patient Pool of Acute Pain in France (2017-2028)
  • Figure 17: Total Patient Pool with Acute Pain in Italy (2017-2028)
  • Figure 18: Patient Pool with Acute Pain by Medical Condition in Italy (2017-2028)
  • Figure 19: Severity Specific Patient Pool of Acute Pain in Italy (2017-2028)
  • Figure 20: Total Patient Pool with Acute Pain in Spain (2017-2028)
  • Figure 21: Patient Pool with Acute Pain by Medical Condition in Spain (2017-2028)
  • Figure 22: Severity Specific Patient Pool of Acute Pain in Spain (2017-2028)
  • Figure 23: Total Patient Pool with Acute Pain in the United Kingdom (2017-2028)
  • Figure 24: Patient Pool with Acute Pain by Medical Condition in the United Kingdom (2017-2028)
  • Figure 25: Severity Specific Patient Pool of Acute Pain in the United Kingdom (2017-2028)
  • Figure 26: Total Patient Pool with Acute Pain in Japan (2017-2028)
  • Figure 27: Patient Pool with Acute Pain by Medical Condition in Japan (2017-2028)
  • Figure 28: Severity Specific Patient Pool of Acute Pain in Japan (2017-2028)
  • Figure 29: Progression of regional anesthetic applications into formal acute pain medicine programs.
  • Figure 30: Treatment Algorithm for Acute Post-operative Pain
  • Figure 31: Acute Pain Flow Sheet for the Evaluation and Treatment of Acute Pain
  • Figure 32: Unmet Needs
  • Figure 33: Market Size of Acute Pain by Value in the 7MM in USD Million (2017-2028)
  • Figure 34: Market Size of Acute Pain by Volume ('000) in the 7MM in USD Million (2017-2028)
  • Figure 35: Market Size of Acute Pain in the US, USD Millions (2017-2028)
  • Figure 36:Market Size of Acute Pain by therapies in the United States, in USD Million (2017-2028)
  • Figure 37: Market Size of Acute Pain by Volume ('000) in the US, USD Millions (2017-2028)
  • Figure 38: Market Size of Acute Pain in Germany, USD Millions (2017-2028)
  • Figure 39: Market Size of Acute Pain by therapies in Germany, in USD Million (2017-2028)
  • Figure 40: Market Size of Acute Pain by Volume ('000) in Germany, USD Millions (2017-2028)
  • Figure 41: Market Size of Acute Pain by Value in France, USD Millions (2017-2028)
  • Figure 42: Market Size of Acute Pain by therapies in France, in USD Million (2017-2028)
  • Figure 43: Market Size of Acute Pain by Volume ('000) in France, USD Millions (2017-2028)
  • Figure 44: Market Size of Acute Pain by Value in Italy, USD Millions (2017-2028)
  • Figure 45: Market Size of Acute Pain by therapies in Italy in USD Million (2017-2028)
  • Figure 46: Market Size of Acute Pain by Volume ('000) in Italy, USD Millions (2017-2028)
  • Figure 47: Market Size of Acute Pain by Value in Spain, USD Millions (2017-2028)
  • Figure 48: Market Size of Acute Pain by therapies in Spain in USD Million (2017-2028)
  • Figure 49: Market Size of Acute Pain by Volume ('000) in Spain, USD Millions (2017-2028)
  • Figure 50: Market Size of Acute Pain by Value in the UK, USD Millions (2017-2028)
  • Figure 51: Market Size of Acute Pain by therapies in the UK in USD Million (2017-2028)
  • Figure 52: Market Size of Acute Pain by Volume ('000) in the UK, USD Millions (2017-2028)
  • Figure 53:Market Size of Acute Pain by Value in Japan, USD Millions (2017-2028)
  • Figure 54: Market Size of Acute Pain by therapies in Japan in USD Million (2017-2028)
  • Figure 55:Market Size of Acute Pain by Volume ('000) in Japan, USD Millions (2017-2028)
  • Figure 56: Market Drivers
  • Figure 57: Market Barriers
Back to Top